News | July 24, 2008

Australia’s Largest Transplant Hospital Begins CardioWest Artificial Heart Certification

July 25, 2008 - The cardiac transplant team from St. Vincent’s Hospital in Sydney, Australia, will travel to Paris July 28-29 to begin the first phase of certification training for the CardioWest temporary total artificial heart (TAH-t).

“We are very excited to be the first hospital in Australia,” said Dr. Paul Jansz, cardiothoracic and transplant surgeon at St. Vincent’s. “As the future CardioWest training center for the Asia-Pacific region, we look forward to expanding the use of this life-saving technology at our hospital and other top transplant hospitals in Australia and New Zealand.”

St. Vincent’s will be the 35th hospital in the world to complete the first phase of certification training. Since performing Australia’s first heart transplant in 1968, St. Vincent’s has been on the cutting edge of cardiac surgery. The hospital’s current one-year survival rate for heart transplant is 95 percent, compared to 86 percent in the U.S. in 2007 (American Heart Association).

The CardioWest artificial heart is the first and only FDA, Health Canada and CE Mark approved temporary total artificial heart. There have been more than 740 implants of the CardioWest, the company said.

For more information:

Related Content

Transplanting Pig Hearts Into Humans One Step Closer
News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
Overlay Init